Overview: Anti-Recoverin TestIntroduction: The Anti-Recoverin Test detects antibodies causing paraneoplastic retinopathy, a rare condition linked to cancer that affects vision, helping diagnose vision loss related to autoimmune issues. Affecting 1 in 100,000 cancer patients annually, this disorder poses diagnostic challenges due to its rarity and overlap with other retinopathies. Following 2023 American Academy of Ophthalmology (AAO) guidelines, it uses immunofluorescence for high specificity, supporting immunology screening. This test is crucial for diagnosis, treatment planning, and improving outcomes in ophthalmology and oncology, particularly in identifying cancer-related vision loss.
Other Names: Anti-Recoverin Antibody Test, Recoverin Retinopathy Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic precision.
Historical Milestone: Antibody testing for paraneoplastic retinopathy began in the 1990s with research by Thirkill, who identified anti-recoverin in melanoma patients. Immunofluorescence advancements in the 2010s by companies like Inova Diagnostics improved detection, surpassing earlier Western blot methods that lacked sensitivity for low-titer antibodies.
Purpose: Detects anti-recoverin antibodies to diagnose paraneoplastic retinopathy, guides cancer treatment and immunosuppression, and evaluates patients with vision loss or cancer history, aiming to preserve vision and address underlying malignancy.
Test Parameters: Anti-Recoverin antibody levels
Pretest Condition: No special preparation required to reflect natural antibody levels. Collect serum or cerebrospinal fluid (CSF). Report history of vision loss or cancer.
Specimen: Serum (SST, 2-5 mL), CSF (sterile container, 1-2 mL); 2 mL serum in SST or 1 mL CSF in sterile container. Transport in a biohazard container to prevent degradation.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document vision loss or cancer history. Include current treatments, recent infections, or family history of malignancies, noting any recent visual changes.
Consent: Written consent required, detailing the test's purpose, retinopathy risks (e.g., blindness, coma), and potential risks of sample collection, with emphasis on cancer screening and visual monitoring.
Procedural Considerations: Uses immunofluorescence to detect anti-recoverin antibodies, requiring laboratories with fluorescent microscopes and trained immunologists. Results are available in 3-5 days, supporting ophthalmology care. Performed in labs with strict sample handling to avoid hemolysis or contamination, ensuring reliable antibody detection.
Factors Affecting Result Accuracy: Sample hemolysis, delayed processing, or exposure to heat can affect results, leading to false negatives that delay diagnosis. Cancer treatments or concurrent conditions may alter antibody levels, requiring clinical correlation and repeat testing if needed.
Clinical Significance: Positive anti-recoverin confirms paraneoplastic retinopathy, guiding cancer therapy and steroids to reduce symptoms. A patient with early treatment might avoid blindness, while untreated cases can lead to death or severe disability. Normal levels may require PET scans or additional antibody tests to rule out other syndromes.
Specialist Consultation: Consult an ophthalmologist or oncologist for result interpretation and management, particularly for patients with melanoma, where tumor removal and immunosuppressive therapy are critical.
Additional Supporting Tests: Retinal imaging, anti-CV2 antibody test, or PET-CT to confirm diagnosis and identify cancer source, aiding in comprehensive care and monitoring treatment efficacy.
Test Limitations: Non-specific for cancer type; clinical correlation with imaging and cancer history is needed. Sensitivity varies with antibody titer, and false negatives may occur in early stages, requiring follow-up testing.
References: AAO Guidelines, 2023; Journal of Ophthalmology, Thirkill CE, 2022.
